Drug Trial Radar · NCT07944326
Cardiovascular and Renal Protection With SGLT Inhibition in Kidney Transplant Recipients: The RENAISSANCE Trial
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
900
Planned (sponsor's estimate)
Start
Apr 1, 2027
Primary completion
Oct 1, 2031
Study completion Mar 1, 2032
Sponsor
- Lead sponsor
- University of British ColumbiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Canadian Institutes of Health Research (CIHR); Lexicon Pharmaceuticals; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- First posted
- Nov 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will examine whether sotagliflozin, a medication that may protect the heart and kidneys, can improve long-term health in people who have received a kidney transplant. The study will compare sotagliflozin with an inactive placebo in approximately 900 adult kidney transplant recipients. Researchers will assess whether the medication can reduce the risk of kidney transplant failure, worsening kidney function, heart problems, stroke, heart attack, heart failure, and death. The study will also closely monitor participants for possible side effects, including infections, dehydration, fractures, and rejection of the transplanted kidney.
Conditions
- Kidney Transplant Recipient
Interventions
SotagliflozinDrug
Sotagliflozin 200 mg PO OD will be administered for 3-4.5 years.
PlaceboDrug
Matching placebo will be administered for 3-4.5 years.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Hierarchical Composite of All-Cause Mortality, Kidney Transplant Loss, Non-Fatal Stroke or Myocardial Infarction, Sustained 40% Decline in eGFR, Heart Failure Events, and Total eGFR SlopeTime frame: From randomization to the end of the study (up to 4.5 years), with eGFR slope assessed from screening to the last on-study drug visit.
- Number of Participants Experiencing Serious Adverse EventsTime frame: From randomization to the end of the study (up to 4.5 years).
- Number of Participants Experiencing Adverse Events Leading to Permanent Study Drug DiscontinuationTime frame: From randomization to the end of the study (up to 4.5 years).
- Number of Participants Experiencing Study Drug-Related Adverse EventsTime frame: From randomization to the end of the study (up to 4.5 years).
- Number of Participants Experiencing Adverse Events of Special InterestTime frame: From randomization to the end of the study (up to 4.5 years).
Locations
25 sites in 7 countries. Site status is shown where the registry gives one.
University of Minnesota
Minneapolis, Minnesota
NewYork-Presbyterian / Weill Cornell Medical Center
New York, New York
UNC Medical Center
Chapel Hill, North Carolina
Royal Prince Alfred Hospital
Sydney, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
University of Alberta
Edmonton, Alberta, Canada
St. Paul's Hospital
Vancouver, British Columbia, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
Queen Elizabeth II Health Sciences Centre
Halifax, Nova Scotia, Canada
St. Joseph's Healthcare Hamilton
Hamilton, Ontario, Canada
Kingston General Hospital
Kingston, Ontario, Canada
London Health Sciences Centre
London, Ontario, Canada
The Ottawa Hospital
Ottawa, Ontario, Canada
St. Michael's Hospital
Toronto, Ontario, Canada
University Health Network
Toronto, Ontario, Canada
Centre de Recherche du CHUM Pavillon R
Montreal, Quebec, Canada
McGill University Health Centre
Montreal, Quebec, Canada
CHU de Québec - Université Laval
Québec, Quebec, Canada
St. Paul's Hospital
Saskatoon, Saskatchewan, Canada
Charité Universitätsmedizin Berlin
Berlin, Germany
Auckland City Hospital
Auckland, New Zealand
Hospital del Mar
Barcelona, Spain
University Hospitals Birmingham
Birmingham, United Kingdom
Royal Free Hospital
London, United Kingdom
St George's University Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.